CRISPR-Cas9-based mutagenesis frequently provokes on-target mRNA misregulation

被引:0
|
作者
Rubina Tuladhar
Yunku Yeu
John Tyler Piazza
Zhen Tan
Jean Rene Clemenceau
Xiaofeng Wu
Quinn Barrett
Jeremiah Herbert
David H. Mathews
James Kim
Tae Hyun Hwang
Lawrence Lum
机构
[1] University of Texas Southwestern Medical Center,Department of Cell Biology
[2] Cleveland Clinic Lerner Research Institute,Department of Quantitative Health Sciences
[3] University of Rochester Medical Center,Department of Biochemistry and Biophysics
[4] University of Texas Southwestern Medical Center,Department of Internal Medicine
[5] University of Texas Southwestern Medical Center,Hamon Center for Therapeutic Oncology Research Department of Biochemistry
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
The introduction of insertion-deletions (INDELs) by non-homologous end-joining (NHEJ) pathway underlies the mechanistic basis of CRISPR-Cas9-directed genome editing. Selective gene ablation using CRISPR-Cas9 is achieved by installation of a premature termination codon (PTC) from a frameshift-inducing INDEL that elicits nonsense-mediated decay (NMD) of the mutant mRNA. Here, by examining the mRNA and protein products of CRISPR targeted genes in a cell line panel with presumed gene knockouts, we detect the production of foreign mRNAs or proteins in ~50% of the cell lines. We demonstrate that these aberrant protein products stem from the introduction of INDELs that promote internal ribosomal entry, convert pseudo-mRNAs (alternatively spliced mRNAs with a PTC) into protein encoding molecules, or induce exon skipping by disruption of exon splicing enhancers (ESEs). Our results reveal challenges to manipulating gene expression outcomes using INDEL-based mutagenesis and strategies useful in mitigating their impact on intended genome-editing outcomes.
引用
收藏
相关论文
共 50 条
  • [1] CRISPR-Cas9-based mutagenesis frequently provokes on-target mRNA misregulation
    Tuladhar, Rubina
    Yeu, Yunku
    Piazza, John Tyler
    Tan, Zhen
    Clemenceau, Jean Rene
    Wu, Xiaofeng
    Barrett, Quinn
    Herbert, Jeremiah
    Mathews, David H.
    Kim, James
    Hwang, Tae Hyun
    Lum, Lawrence
    [J]. NATURE COMMUNICATIONS, 2019, 10 (1)
  • [2] The Advance of CRISPR-Cas9-Based and NIR/CRISPR-Cas9-Based Imaging System
    Qiao, Huanhuan
    Wu, Jieting
    Zhang, Xiaodong
    Luo, Jian
    Wang, Hao
    Ming, Dong
    [J]. FRONTIERS IN CHEMISTRY, 2021, 9
  • [3] CRISPR-Cas9-Based Mutagenesis of the Mucormycosis-Causing Fungus Lichtheimia corymbifera
    Ibragimova, Sandugash
    Szebenyi, Csilla
    Sinka, Rita
    Alzyoud, Elham I.
    Homa, Monika
    Vagvoelgyi, Csaba
    Nagy, Gabor
    Papp, Tamas
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (10) : 1 - 11
  • [4] Improving CRISPR/ Cas9 On-target Specificity
    Jamal, Muhammad
    Ullah, Arif
    Naeem, Muhammad Ahsan
    Tyagi, Rohit
    Habib, Zeshan
    Rehman, Khaista
    [J]. CURRENT ISSUES IN MOLECULAR BIOLOGY, 2018, 26 : 65 - 80
  • [5] Keeping CRISPR/Cas on-Target
    Jamal, Muhammad
    Khan, Faheem Ahmed
    Da, Lin
    Habib, Zeshan
    Dai, Jinxia
    Cao, Gang
    [J]. CURRENT ISSUES IN MOLECULAR BIOLOGY, 2016, 20 : 1 - 12
  • [6] CRISPR-Cas9-based Photoactivatable Transcription System
    Nihongaki, Yuta
    Yamamoto, Shun
    Kawano, Fuun
    Suzuki, Hideyuki
    Sato, Moritoshi
    [J]. CHEMISTRY & BIOLOGY, 2015, 22 (02): : 169 - 174
  • [7] CRISPR-Cas9-based target validation for p53-reactivating model compounds
    Wanzel, Ichael
    Vischedyk, Jonas B.
    Gittler, Miriam P.
    Gremke, Niklas
    Seiz, Julia R.
    Hefter, Mirjam
    Noack, Magdalena
    Savai, Rajkumar
    Mernberger, Marco
    Charles, Joel P.
    Schneikert, Jean
    Bretz, Anne Catherine
    Nist, Andrea
    Stiewe, Thorsten
    [J]. NATURE CHEMICAL BIOLOGY, 2016, 12 (01) : 22 - +
  • [8] CRISPR-Cas9-based target validation for p53-reactivating model compounds
    Wanzel M.
    Vischedyk J.B.
    Gittler M.P.
    Gremke N.
    Seiz J.R.
    Hefter M.
    Noack M.
    Savai R.
    Mernberger M.
    Charles J.P.
    Schneikert J.
    Bretz A.C.
    Nist A.
    Stiewe T.
    [J]. Nature Chemical Biology, 2016, 12 (1) : 22 - 28
  • [9] Chromothripsis as an on-target consequence of CRISPR–Cas9 genome editing
    Mitchell L. Leibowitz
    Stamatis Papathanasiou
    Phillip A. Doerfler
    Logan J. Blaine
    Lili Sun
    Yu Yao
    Cheng-Zhong Zhang
    Mitchell J. Weiss
    David Pellman
    [J]. Nature Genetics, 2021, 53 : 895 - 905
  • [10] CRISPR-Cas9-based target validation for p53-reactivating model compounds
    Wanzel, M.
    Vischedyk, J.
    Gittler, M.
    Gremke, N.
    Mernberger, M.
    Charles, J.
    Schneikert, J.
    Bretz, A. C.
    Nist, A.
    Stiewe, T.
    [J]. EUROPEAN JOURNAL OF CANCER, 2016, 61 : S122 - S122